Glucocorticoid Receptor 

 186 Products   186 Products   1696 Diseases   95004 News 


«12...222223224225226227228229230231232...10661067»
  • ||||||||||  dexamethasone / Generic mfg.
    Postcovid-19 cavitary pulmonary lesions (Display area) -  Dec 14, 2022 - Abstract #CPLF2023CPLF_223;    
    11 patients received antibiotic therapy and treatment at dexamethasone during the COVVI-19...Conclusion The presence of cavitation is considered an atypical manifestation of the COVID-19, suggesting an alternative diagnosis. Cavoire lesions in patients with COVID-19 requires a differential diagnosis for superimposed infections, neoplasms, mycobacteriosis, pulmonary embolism, tuberculosis, fungal diseases, pulmonary infarction or thrombembolic vascular disease associated with covid- 19.
  • ||||||||||  betamethasone / Generic mfg.
    Enrollment open, Trial completion date, Trial primary completion date:  Betamethasone (Betapred®) as Premedication for Reducing Postoperative Vomiting and Pain After Tonsillectomy (clinicaltrials.gov) -  Dec 14, 2022   
    P4,  N=100, Recruiting, 
    Cavoire lesions in patients with COVID-19 requires a differential diagnosis for superimposed infections, neoplasms, mycobacteriosis, pulmonary embolism, tuberculosis, fungal diseases, pulmonary infarction or thrombembolic vascular disease associated with covid- 19. Unknown status --> Recruiting | Trial completion date: Jun 2022 --> Jun 2024 | Trial primary completion date: Dec 2021 --> Dec 2023
  • ||||||||||  dexamethasone injection / Generic mfg.
    Enrollment change, Trial withdrawal, Surgery:  SHDD: High Dose Steroids for Dysphagia (clinicaltrials.gov) -  Dec 14, 2022   
    P=N/A,  N=0, Withdrawn, 
    N=320 --> 224 N=40 --> 0 | Unknown status --> Withdrawn
  • ||||||||||  Nucala (mepolizumab) / GSK
    Journal:  Mepolizumab as a Potential Protective Factor of COVID-19 Mortality: A Case Report of Chronic Bronchitis and Asthma in an Elderly Patient. (Pubmed Central) -  Dec 14, 2022   
    His medications included mepolizumab, aclidinium, ramipril, diltiazem, aspirin, albuterol sulfate, and micronized budesonide/micronized formoterol fumarate dihydrate...COVID-19 pneumonia was diagnosed, and the patient was admitted to the hospital, where he was treated with acetaminophen, amoxicillin, dexamethasone, and supplemental oxygen...He was free of all symptoms after 21 days. CONCLUSIONS This case of a 75-year-old man who presented with mild COVID-19 supports the findings from other reports of improvement in clinical outcomes for some patients with asthma who received treatment with mepolizumab.
  • ||||||||||  dexamethasone / Generic mfg.
    Preclinical, Journal:  Glucocorticoid receptor hypersensitivity enhances inflammatory signaling and inhibits cell cycle progression in porcine PBMCs. (Pubmed Central) -  Dec 13, 2022   
    We previously discovered that a natural gain-of-function Ala610Val substitution in the porcine GR aggravates response of pigs to lipopolysaccharide (LPS)-induced endotoxemia, which can be alleviated by dexamethasone (DEX) pretreatment...In contrast, when stimulated by DEX treatment, the Val allele orchestrated several genes involved in anti-inflammatory responses during infection. This study provides novel insights into the impact of GR hypersensitivity on the fate and function of immune cells, which may be useful for endotoxemia therapy.
  • ||||||||||  hydrocortisone / Generic mfg.
    Journal:  Sleep patterns in patients treated for non-secreting intra- and parasellar tumors: A self-report case-control study. (Pubmed Central) -  Dec 13, 2022   
    Additionally, when treating patients surgically, especially by transcranial approach, damaging the suprachiasmatic nucleus should be avoided. Furthermore, circadian hydrocortisone replacement therapy ideally with dual-release hydrocortisone - if possible, in a dose not more than 20mg daily - that resembles physiological cortisol levels more closely may be beneficial and could improve sleep patterns and sleep-related quality of life.
  • ||||||||||  triamcinolone acetonide / Generic mfg.
    Journal:  The objective evaluation of triamcinolone acetonide efficacy in keloids management using Antera3D® imaging system. (Pubmed Central) -  Dec 13, 2022   
    In this series, for Antera3D® scores there were statistically significant differences in color, protrusion, melanin and hemoglobin expression levels before and after treatment. The device directly shows the treatment changes, measured objectively and accurately, without bias of traditional evaluation scoring scale.Antera3D® system guarantees an objective evaluation of effectiveness of scar treatment enabling clinicians to modulate the therapy according to the scores registered.
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  A practical update on the management of patients with COVID-19. (Pubmed Central) -  Dec 13, 2022   
    Dexamethasone and interleukin-6 inhibitors have been the mainstay of treatment for severe to critical COVID-19 requiring hospitalisation...In particular, the development of neutralising monoclonal antibodies and novel antivirals represents a welcome expansion in the armamentarium against COVID-19, not only therapeutically to reduce mortality but also because they can be used in mild or moderate disease to prevent hospitalisation. This update is based on guidance from NHS England as well as the World Health Organization, and provides practical support and guidance to all clinicians involved or interested in the management of COVID-19 patients, whether based in community, outpatient or inpatient settings.
  • ||||||||||  dexamethasone / Generic mfg., pamidronate disodium / Generic mfg.
    Preclinical, Journal:  Significance of medication discontinuation on bisphosphonate-related jaw osteonecrosis in a rat model. (Pubmed Central) -  Dec 13, 2022   
    Histologically, group I showed a significantly higher percentage of necrotic bone than group II (51.93 ± 12.75%, p < 0.05) and a higher number of detached osteoclasts in TRAP staining. With discontinuation of medication for at least 1 week in rats, the effects of BPs on alveolar bone are suppressed and bone turnover and osteoclast functions are restored.
  • ||||||||||  Breztri Aerosphere (budesonide/formoterol fumarate/glycopyrronium) / AstraZeneca
    Trial completion date, Trial primary completion date, Real-world evidence, Patient reported outcomes, Real-world:  RECORD: REported Outcomes in COPD With Trixeo in Real worlD in Germany (clinicaltrials.gov) -  Dec 13, 2022   
    P=N/A,  N=500, Recruiting, 
    With discontinuation of medication for at least 1 week in rats, the effects of BPs on alveolar bone are suppressed and bone turnover and osteoclast functions are restored. Trial completion date: Sep 2023 --> Mar 2024 | Trial primary completion date: Sep 2023 --> Mar 2024
  • ||||||||||  dexamethasone / Generic mfg., lenalidomide / Generic mfg.
    Review, Journal:  Recent Advances in the Treatment and Supportive Care of POEMS Syndrome. (Pubmed Central) -  Dec 12, 2022   
    Lenalidomide and dexamethasone is a proven therapy in patients ineligible for ASCT. In this review article, we tackle the diagnostic approach and discuss the latest treatment modalities of this rare debilitating disease.
  • ||||||||||  dexamethasone / Generic mfg., cisplatin / Generic mfg.
    Preclinical, Journal:  Liquid Crystalline Nanoparticles Conjugated with Dexamethasone Prevent Cisplatin Ototoxicity In Vitro. (Pubmed Central) -  Dec 12, 2022   
    To confirm this result, also cell morphology, cell cycle and glucocorticoids receptor expression were investigated. In conclusion, the NPD system has thus preliminarily shown the potential to improve the therapeutic efficacy of treatments delivered in the inner ear and prevent drug-induced ototoxicity.
  • ||||||||||  Decadron (dexamethasone) / Merck (MSD), Leukine (sargramostim) / Partner Therap
    Trial completion date, Trial termination, Trial primary completion date:  Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia (clinicaltrials.gov) -  Dec 12, 2022   
    P2/3,  N=11, Terminated, 
    Trial completion date: Dec 2022 --> Dec 2024 | Trial primary completion date: Dec 2022 --> Dec 2024 Trial completion date: Dec 2021 --> Jul 2022 | Completed --> Terminated | Trial primary completion date: Dec 2021 --> Jul 2022; Slow Accrual